• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

    3/31/25 4:10:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CLDI alert in real time by email
    • Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform
    • Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumors
    • Commencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital
    • 14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma

    SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights.

    "Calidi continues to make great progress on all three of our platforms; our systemic asset CLD-400 proved it can deliver a gene therapy payload to targeted tumors, we filed an IND for our solid tumor asset CLD-201, and our CLD-101 program treating high-grade glioma is advancing in two Phase 1 trials," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "We think our multi-modal mechanism of action is a game changer in treating multiple deadly cancers, including metastatic cancer and lung cancer, solid tumors and high-grade glioma."

    Fourth Quarter 2024 and Recent Corporate Developments

    • New data showed that a single dose of a tumor-selective triple knockout ("3KO") RT virus genetically engineered to encode a specific immune-boosting payload (undisclosed) increased the antitumor immune response. These increased shifts in immune composition, driven by virotherapy encoding a payload, ultimately led to complete eradication of certain tested tumors in the preclinical model.

    • In March 2025, Calidi filed an IND for a company sponsored, open label dose escalation trial of CLD-201 in adult patients with solid tumors, specifically with the indications of breast cancer, head & neck squamous cell carcinoma, and soft tissue sarcoma.

    • In February 2025, Northwestern University hospital started recruiting for the CLD-101 Phase 1 clinical trial in patients with newly diagnosed high-grade glioma, an aggressive and often fatal form of brain cancer. This physician-led and NCI sponsored clinical trial, led by prominent experts Dr. Maciej Lesniak and Dr. Roger Stupp, builds on the promising results from a prior Phase 1 trial involving 12 patients treated with a single dose of CLD-101 published in the prestigious journal The Lancet Oncology.

    • City of Hope and Calidi announced the 14th patient treated in a physician-sponsored Phase 1 trial assessing the safety and feasibility of a multi-dosing regimen to treat recurrent high-grade glioma.  This program has secured $12 million award from the California Institute for Regenerative Medicine (CIRM) to support this groundbreaking study.



    Upcoming Anticipated Milestones

    • Q2 2025: Payload and lead candidate information revealed on CLD-400 systemic platform
    • Q2 2025: First patient dosed in CLD-101 Phase 1 trial in collaboration with Northwestern University for newly diagnosed high-grade glioma patients
    • Q3 2025: First patient dosed in CLD-201 Phase 1 trial



    Fourth Quarter 2024 Financial Results

    The company reported a net loss attributable to common stockholders of $4.1 million, or $0.27 per share, for the three months ended December 31, 2024, compared to a net loss attributable to common stockholders of $8.2 million, or $0.23 per share, for the same period in 2023.

    Research and development expenses were $1.8 million for the three months ended December 31, 2024, compared to $4.0 million for the comparable period in 2023, respectively.

    General and administrative expenses were $2.2 million for the three months ended December 31, 2024, compared to $5.9 million for the comparable period in 2023, respectively.

    Full Year 2024 Financial Results

    The company reported a net loss attributable to common stockholders of $23.8 million, or $2.97 per share, for the year ended December 31, 2024, compared to a net loss attributable to common stockholders of $29.2 million, or $17.33 per share, for the year ended December 31, 2023.

    Research and development expenses were $8.9 million for the year ended December 31, 2024, compared to $13.0 million for the year ended December 31, 2023, respectively.

    General and administrative expenses were $12.9 million for the year ended December 31, 2024, compared to $16.0 million for the year ended December 31, 2023, respectively.

    The company had approximately $9.6 million in cash and $0.2 million in restricted cash as of December 31, 2024, compared to $1.9 million in cash and $0.2 million in restricted cash as of December 31, 2023.

    About Calidi Biotherapeutics

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predicts," "project," "should," "towards," "would" as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi's therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi's current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company's periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time.

    Contacts:

    For Investors and Media:

    Dave Gentry, CEO

    RedChip Companies, Inc.

    1-407-644-4256

    [email protected]





    CALIDI BIOTHERAPEUTICS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except for par value data)
     
      December 31, 
      2024  2023 
           
    ASSETS        
    CURRENT ASSETS        
    Cash $9,591  $1,949 
    Prepaid expenses and other current assets  636   2,354 
    Total current assets  10,227   4,303 
    NONCURRENT ASSETS        
    Machinery and equipment, net  869   1,270 
    Operating lease right-of-use assets, net  2,934   4,073 
    Other noncurrent assets  152   373 
    TOTAL ASSETS $14,182  $10,019 
    LIABILITIES AND EQUITY (DEFICIT)        
    CURRENT LIABILITIES        
    Accounts payable $2,072  $2,796 
    Related party accounts payable  2   81 
             
    Accrued expenses and other current liabilities  1,858   4,896 
    Related party accrued expenses and other current liabilities  480   536 
             
    Term notes payable, net of discount, including accrued interest  251   529 
    Related party term notes payable, net of discount, including accrued interest  2,702   278 
             
    Related party bridge loan payable, including accrued interest  223   — 
    Related party other current liability  638   — 
    Finance lease liability, current  66   81 
    Operating lease right-of-use liability, current  1,204   1,035 
    Total current liabilities  9,496   10,232 
    NONCURRENT LIABILITIES        
    Operating lease right-of-use liability, noncurrent  1,845   3,037 
    Finance lease liability, noncurrent  145   216 
    Promissory note  600   — 
    Related party term notes payable, net of discount, including accrued interest  —   2,060 
    Other noncurrent liabilities  —   1,500 
    Related party other noncurrent liabilities  —   538 
             
    Warrant liability  119   623 
    Related party warrant liability  9   48 
    TOTAL LIABILITIES  12,214   18,254 
    TOTAL EQUITY (DEFICIT)  1,968   (8,235)
    TOTAL LIABILITIES AND EQUITY (DEFICIT) $14,182  $10,019 





    CALIDI BIOTHERAPEUTICS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (In thousands, except per share data)
     
      Year Ended December 31, 
      2024  2023 
    OPERATING EXPENSES        
    Research and development $(8,878) $(13,008)
    General and administrative  (12,898)  (15,984)
    Total operating expense  (21,776)  (28,992)
    Loss from operations  (21,776)  (28,992)
    OTHER INCOME (EXPENSES), NET        
    Interest expense  (372)  (329)
    Interest expense – related party  (561)  (740)
             
    Series B convertible preferred stock financing costs – related party  —   (2,680)
    Change in fair value of debt, other liabilities, and derivatives  285   (200)
    Change in fair value of debt, other liabilities, and derivatives – related party  39   1,378 
             
    Grant income  181   2,885 
    Debt extinguishment  —   (139)
    Debt extinguishment – related party  —   (332)
             
    Other income (expense), net  9   (51)
    Total other income (expenses), net  (419)  (208)
    LOSS BEFORE INCOME TAXES  (22,195)  (29,200)
    Income tax provision  (14)  (16)
    NET LOSS $(22,209) $(29,216)
    Net loss attributable to noncontrolling interest  (66)  — 
    NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST  (22,143)  (29,216)
    Deemed dividend on warrants  (1,671)  — 
    NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS  (23,814)  (29,216)
    Net loss per share; basic and diluted $(2.97) $(17.33)
    Weighted average common shares outstanding; basic and diluted  8,005   1,686 





    Primary Logo

    Get the next $CLDI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLDI

    DatePrice TargetRatingAnalyst
    11/22/2023$11.00Buy
    H.C. Wainwright
    10/9/2023$9.00Outperform
    Robert W. Baird
    More analyst ratings

    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

      SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, today announced the presentation of its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (ASCO) Annual Meeting. Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical

      6/2/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

      SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL. The first candidate developed using RTNova is a vaccinia virus (virotherapy) that is engineered to be tumor selective and produced in an enveloped form that allows the virus to surv

      4/28/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

      4/25/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Poma Eric E

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:05:05 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Poma Eric E

      3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:01:32 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Stewart Alan R. was granted 12,771 shares, increasing direct ownership by 79% to 28,976 units (SEC Form 4)

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      1/3/25 5:27:37 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Calidi Biotherapeutics Inc.

      DEFA14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/23/25 4:01:32 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Calidi Biotherapeutics Inc.

      DEF 14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/23/25 4:00:12 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Calidi Biotherapeutics Inc.

      SCHEDULE 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      5/15/25 3:14:34 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

      11/22/23 7:15:52 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

      Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

      10/9/23 7:23:07 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

      SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      11/14/24 2:05:25 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

      SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      9/11/24 4:04:09 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Financials

    Live finance-specific insights

    See more
    • Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

      Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

      3/31/25 4:10:00 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

      10/25/24 9:00:00 AM ET
      $CLDI
      $NXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi: https://www.redchip.com/assets/access/cldi_accessGorilla Technology: https://www.redchip.com/assets/access/grrr_accessIn an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloombe

      10/18/24 8:45:00 AM ET
      $BOXL
      $CLDI
      $GRRR
      Other Consumer Services
      Real Estate
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care